Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Masofaniten by ESSA Pharma for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
Masofaniten is under clinical development by ESSA Pharma and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to...
Data Insights
Risk adjusted net present value: What is the current valuation of ESSA Pharma's Masofaniten?
Masofaniten is a small molecule commercialized by ESSA Pharma, with a leading Phase I program in Castration-Resistant Prostate Cancer (CRPC)....